【三生制药(01530.HK)与辉瑞就PD-1/VEGF双特异性抗体(SSGJ-707)订立许可协议】三生制药(01530.HK)发布公告,于2025年5月19日,公司、沈阳三生制药有限责任公司(沈阳三生,公司的全资附属公司)及辉瑞公司(辉瑞)已订立独家许可协议。三生国健药业(上海)股份有限公司(三生国健,公司附属公司)亦将透过加入协议作为签署方加入。

金融界
20 May
三生制药(01530.HK)发布公告,于2025年5月19日,公司、沈阳三生制药有限责任公司(沈阳三生,公司的全资附属公司)及辉瑞公司(辉瑞)已订立独家许可协议。三生国健药业(上海)股份有限公司(三生国健,公司附属公司)亦将透过加入协议作为签署方加入。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10